Integrin antagonists for transplant immunosuppression: Panacea or peril?

Immunotherapy

Volumn 3, Issue 3, 2011, Pages 305-307

  Kitchens, William H ^a   Larsen, Christian P ^a   Ford, Mandy L ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

immunosuppression; integrins; LFA 1; transplantation; VLA 4

Indexed keywords

BELATACEPT; CYCLOSPORIN; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTEGRIN; INTEGRIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ODULIMOMAB; PREDNISONE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; AUTOIMMUNE DISEASE; DRUG DOSE COMPARISON; DRUG RECALL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; REVIEW; SIDE EFFECT; TRANSPLANTATION; VIRUS REACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA4BETA1; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MICE; MODELS, ANIMAL; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 79952668647     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.113     Document Type: Review

References (20)

1. Vincenti F, Charpentier B, Vanrenterghem Y et al.: A Phase III Study of Belatacept-based Immunosuppression Regimens Versus Cyclosporine in Renal Transplant Recipients (BENEFIT study). Am. J. Transplant. 10(3), 535-546 (2010).
2. Evans R, Patzak I, Svensson L et al.: Integrins in immunity. J. Cell Sci. 122(Pt 2), 215-225 (2009).
3. Cox D, Brennan M, Moran N: Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 9(10), 804-820 (2010).
4. Isobe M, Suzuki J, Yamazaki S, Sekiguchi M: Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice. Transplantation 62(3), 411-413 (1996). (Pubitemid 26277351)
5. Paul LC, Davidoff A, Benediktsson H, Issekutz TB: The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation 55(5), 1196-1199 (1993). (Pubitemid 23150763)
6. Nicolls MR, Coulombe M, Yang H, Bolwerk A, Gill RG: Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-g or IL-4. J. Immunol. 164(7), 3627-3634 (2000). (Pubitemid 30169816)
7. Stegall MD, Ostrowska A, Haynes J, Karrer F, Kam I, Gill RG: Prolongation of islet allograft survival with an antibody to vascular cell adhesion molecule 1. Surgery 118(2), 366-369; discussion 369-370 (1995).
8. Molossi S, Elices M, Arrhenius T, Diaz R, Coulber C, Rabinovitch M: Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J. Clin. Invest. 95(6), 2601-2610 (1995).
9. Yang H, Issekutz TB, Wright JR: Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation 60(1), 71-76 (1995).
10. Corbascio M, Ekstrand H, Osterholm C et al.: CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely. Transpl. Immunol. 10(1), 55-61 (2002). (Pubitemid 34863326)
11. Nicolls MR, Coulombe M, Beilke J, Gelhaus HC, Gill RG: CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways. J. Immunol. 169(9), 4831-4839 (2002). (Pubitemid 35217146)
12. Arefanian H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR: Short-term administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induce tolerance to neonatal porcine islet xenografts in mice. Diabetes 59(4), 958-966 (2010).
13. Badell IR, Russell MC, Thompson PW et al.: LFA-1-specific therapy prolongs allograft survival in rhesus macaques. J. Clin. Invest. 120(12), 4520-4531 (2010).
14. Hourmant M, Bedrossian J, Durand D et al.: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 62(11), 1565-1570 (1996). (Pubitemid 27009911)
15. Vincenti F, Mendez R, Pescovitz M et al.: A Phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am. J. Transplant. 7(7), 1770-1777 (2007). (Pubitemid 46905435)
16. Posselt AM, Bellin MD, Tavakol M et al.: Islet transplantation in Type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am. J. Transplant. 10(8), 1870-1880 (2010).
17. Turgeon NA, Avila JG, Cano JA et al.: Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am. J. Transplant. 10(9), 2082-2091 (2010).
18. Carson KR, Focosi D, Major EO et al.: Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10(8), 816-824 (2009).
19. Tyler KL: Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann. Neurol. 68(3), 271-274 (2010).
20. Neff RT, Hurst FP, Falta EM et al.: Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 86(10), 1474-1478 (2008).